



Lloyd-Lewis, B. (2022). Multidimensional Fluorescence Imaging of Embryonic and Postnatal Mammary Gland Development. In M. DM. Vivanco (Ed.), *Mammary Stem Cells: Methods and Protocols* (2 ed., pp. 19-48). (Methods in Molecular Biology; Vol. 2471). Springer. https://doi.org/10.1007/978-1-0716-2193-6_2

Peer reviewed version

License (if available):
Unspecified

Link to published version (if available):
[10.1007/978-1-0716-2193-6_2](https://doi.org/10.1007/978-1-0716-2193-6_2)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the accepted author manuscript (AAM). The final published version (Version of Record) can be found on the publisher's website. The copyright of any third-party content, such as images, remains with the copyright holder.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

1 **Multidimensional fluorescence imaging of embryonic and postnatal mammary**
2 **gland development**

3

4 Claudia Carabaña^{1,2}, Bethan Lloyd-Lewis^{3§}

5

6 ¹ Institut Curie, PSL Research University, INSERM, CNRS, Paris, France

7 ² Sorbonne University, UPMC University of Paris VI, Paris, France

8 ³ School of Cellular and Molecular Medicine, University of Bristol, Biomedical Sciences
9 Building, Bristol, BS8 1TD, UK.

10

11 §Author correspondence (bethan.lloyd-lewis@bristol.ac.uk)

12

13 **Abstract**

14

15 Multidimensional fluorescence imaging represents a powerful approach for studying the
16 dynamic cellular processes underpinning the development, function and maintenance of the
17 mammary gland. Here, we describe key multidimensional imaging strategies that enable
18 visualisation of mammary branching morphogenesis and epithelial cell fate dynamics during
19 postnatal and embryonic mammary gland development. These include 4-dimensional intravital
20 microscopy and *ex vivo* imaging of embryonic mammary cultures, in addition to methods that
21 facilitate 3-dimensional imaging of the ductal epithelium at single cell resolution within its
22 native stroma. Collectively, these approaches provide a window into mammary developmental
23 dynamics, and the perturbations underlying tissue dysfunction and disease.

24

25 **Running title:** Multidimensional imaging in the mammary gland

26 **Keywords:** intravital microscopy, multidimensional imaging, 3D imaging, 4D imaging,
27 mammary gland morphogenesis, mammary embryonic development, *ex vivo* culture, optical
28 tissue clearing, *in vivo* imaging.

29

30 **1. Introduction**

31 Biological imaging is a fundamental and universal tool in the life sciences. For over 80 years,
32 researchers have harnessed microscopy to reveal the inner workings of the mammary gland,
33 a secretory organ essential for the survival of over 5000 mammalian species [1]. Light and
34 electron microscopy of fixed tissue sections and cells are mainstay tools in a mammary gland
35 biologist's armoury. While immensely useful, two-dimensional (2D) static analyses are limited
36 in their ability to provide detailed topological and/or dynamic functional information. Thus, to
37 fully comprehend the intricate organisation of the branched mammary epithelium, including
38 the dazzling architecture of the lactating mammary gland, three-dimensional (3D; x-, y-, z-)
39 imaging is essential. Moreover, interrogating the inherently dynamic cellular processes
40 underpinning this complex tissue demands the ability to visualise mammary epithelial and
41 stromal cells by live, four-dimensional (4D; x-,y-, z-, t-) imaging [2].

42

43 Due to its widespread accessibility and flexible multicolour acquisition capabilities, confocal
44 laser scanning microscopy (CLSM) is a commonly used optical sectioning technique for
45 volumetric fluorescence imaging [3]. However, conventional confocal modalities rely on single-
46 photon excitation wavelengths in the visible range for imaging, which suffer from tissue light
47 scattering and absorption. This limits confocal microscopy to depths of ~100 μm in most
48 tissues [3, 4]. As such, microscopes equipped with pulsed, infrared multiphoton lasers are
49 favoured for deep tissue imaging. Alongside decreased photo-toxicity, multiphoton infrared
50 excitation is less prone to light scattering and absorption, enabling deeper penetration and
51 tissue imaging depths of up to 1 mm [5, 6]. These features make multiphoton systems
52 particularly useful for *in vivo* fluorescence imaging by intravital microscopy (IVM).

53

54 In this chapter, we describe strategies for high-resolution, multidimensional imaging of live and
55 fixed mammary tissues using CLSM and multiphoton microscopy. These include step-by-step
56 protocols for 4D imaging of the adult and embryonic mammary gland using IVM and *ex vivo*
57 imaging of embryonic cultures respectively. We also describe approaches that facilitate high-
58 resolution volumetric imaging of the mammary epithelium within its native stroma. These
59 methodologies are particularly useful in contexts that demand the ability to visualise large
60 regions of the mammary epithelium at high spatiotemporal resolutions, such as in genetic-fate
61 mapping studies focused on delineating the differentiation potential and capacity of distinct
62 populations of mammary progenitor cells [2, 7, 8]. Importantly, the approaches outlined enable
63 *in situ* visualisation of the dynamic interplay between mammary epithelial cells and their
64 stromal microenvironment. While not discussed herein, many of the described protocols are
65 also compatible with mammary tumour imaging, providing important insights into breast
66 cancer cell biology [9–12].

67 IVM is a powerful technique that facilitates high-resolution, real-time fluorescence imaging of
68 cells deep inside live animals [2, 13]. For short-term, acute IVM under non-recovery
69 anaesthesia, mammary gland tissues and tumours can be made accessible to the
70 microscope's objective via a surgical 'skin-flap' incision [14, 15]. Longitudinal IVM studies,
71 however, require the surgical implantation of an imaging window to protect and provide optical
72 access to tissues during repeated imaging sessions [9, 16–18]. Here, we describe the surgical
73 procedure for implanting mammary imaging windows (MIW), based on protocols developed
74 for their similarly-designed abdominal counterparts [17, 19, 20]. These imaging windows
75 consist of a glass cover-slipped titanium frame that can be fixed above tissues using a purse-
76 string suture. Alongside, we suggest methods for re-tracing regions of interest in consecutive
77 imaging sessions, facilitating *in situ* visualisation of specific mammary epithelial cells and
78 tissue structures for extended periods of time. For studies focused on the embryonic mammary
79 gland, we describe methods for high-resolution, time-resolved CLSM and multiphoton imaging
80 of embryonic mammary buds established in *ex vivo* culture [21–23]. This represents a highly
81 tractable system for interrogating epithelial cell fate dynamics and behaviours during
82 embryonic mammogenesis, a fundamental phase in mammary gland development that
83 remains inaccessible to IVM.

84

85 Finally, we outline strategies for high-resolution, wholemount immunostaining and 3D
86 visualisation of fixed mammary tissues, aimed at circumventing issues associated with
87 antibody penetration and depth of imaging in this optically-opaque organ. This includes an
88 enzymatic digestion-based procedure that facilitates improved deep tissue immunostaining
89 and whole gland imaging of slide-mounted tissues [24–27]. This approach, however, risks
90 proteolytic-mediated damage to mammary epithelial and stromal cells, limiting its utility in
91 some contexts. Consequently, we also provide two optical tissue clearing methods that enable
92 high-resolution, deep tissue mammary gland imaging in the absence of enzymatic digestion
93 or mechanical dissection; namely 'see deep brain' (SeeDB) [28] and 'clear unobstructed brain
94 imaging cocktails' (CUBIC) [29]. By mitigating tissue light scattering caused by cellular and
95 extracellular components with different refractive indices (RIs), these methods allow for the
96 visualisation of expansive regions of the mammary epithelial tree at single-cell resolution
97 within its native stroma [11, 30–35]. These fixed tissue methods are particularly valuable when
98 applied downstream of *in vivo/ex vivo* live-imaging, allowing mammary cells visualised in 4D
99 to be further characterised by immunostaining for biomarkers of interest. The refinement of
100 the imaging approaches described herein - and their application to novel experimental models
101 and methods for visualising distinct cells and cellular processes – will continue to provide
102 important insights into mammary gland and breast cancer biology.

103 **2. Materials**

104 **2.1 Materials for mammary imaging window (MIW) preparation**

- 105 1. Custom-made titanium MIW (See **Note 1**).
- 106 2. Glass coverslips (12 mm).
- 107 3. 100% Ethanol - prepare 70% (v/v) for use.
- 108 4. 100% acetone.
- 109 5. Cyanoacrylate-based glass glue.
- 110 6. Cotton swabs.
- 111 7. Sterile 0.9% saline.
- 112 8. *Optional step*: Sterile 1 ng/ml Poly(L-amino acid)-polyethylene glycol/poly(L-lysine)-
113 polyethylene glycol (PLL-g-PEG) solution prepared in 10 mM HEPES buffer, pH 7.4.

114 **2.2 Surgical instruments and equipment for intravital imaging**

- 115 1. Extra fine Graefe forceps.
- 116 2. Straight Bonn surgical scissors.
- 117 3. *Optional*: Needle holder.
- 118 4. Autoclave pouches.
- 119 5. Bead steriliser.
- 120 6. Sterile surgical gloves, gown, hair net and face mask.
- 121 7. Sterile surgical drapes.
- 122 8. Sterile cotton gauze swabs.
- 123 9. Isoflurane inhalation anaesthetic.
- 124 10. Isoflurane vaporiser (Vet Tech Solutions) with oxygen supply.
- 125 11. Anaesthetic scavenger unit (Vet Tech Solutions).
- 126 12. Anaesthesia induction box/cage.
- 127 13. Heat pad / heated operating stage.
- 128 14. Analgesics e.g. 0.3 mg/ml buprenorphine hydrochloride (Temgesic).
- 129 15. Physiological saline solution.
- 130 16. 1 ml Syringe and 25-guage needle.
- 131 17. Ophthalmic ointment.
- 132 18. Tape.
- 133 19. Pet hair clipper.
- 134 20. *Optional*: depilatory cream.
- 135 21. Antiseptic surgical scrub – e.g. Betadine.
- 136 22. Sterile non-absorbable polypropylene surgical suture (4-0) (See **Note 2**).

137 **2.3 Intravital microscopy (IVM)**

- 138 1. Multiphoton confocal microscope surrounded by a heated dark box (e.g. Nikon A1R
139 MP, equipped with a Spectra-Physics Insight Deepsee laser, conventional and
140 resonant scanners and GaAsP non-descanned detectors).
- 141 2. Long-working distance objectives (e.g. Nikon, 25×/NA1.1 2.0 mm WD water immersion
142 objective).
- 143 3. Custom-made imaging window stabilisers e.g. microscope stage insert or imaging box.
- 144 4. Physiological saline solution.
- 145 5. Syringe and butterfly wing needle (for long-term (>3 h) imaging).
- 146 6. Mouse vital sign monitor (e.g. MouseOx Plus, Starr Life Sciences).
- 147 7. *Optional*: Injectable fluorescent probes to label mammary cells or structures of interest.
- 148 8. Image analysis software and processing tools: e.g. ImageJ (<https://imagej.nih.gov/ij/>),
149 Imaris (<http://www.bitplane.com/>).

150

151 **2.4 Materials for embryonic mammary gland dissection**

- 152 1. Timed-pregnant mice e.g. fluorescent reporter mouse models (*Lgr5-GFP* [36] or
153 *Rosa26-mTmG* reporter strains [37]).
- 154 2. 1 ml syringe and 25-gauge needles.
- 155 3. Dissection tools: micro-dissecting scissors, spring scissors, Dumont #5 forceps and
156 curved micro-dissecting forceps.
- 157 4. 100 mm diameter Petri dish.
- 158 5. 24 well plates.
- 159 6. Stereoscopic dissecting microscope with transmitted illumination.
- 160 7. Sterile phosphate-buffered saline solution (PBS).
- 161 8. Embryonic culture medium: DMEM/F-12, 2 mM GlutaMAX™, 10% Fetal Bovine Serum
162 (FBS) (v/v) and 20 U/ml Penicillin-Streptomycin (PS).
- 163 9. *Optional (for Cre-inducible reporter models)*: Tamoxifen free base (MP Biomedicals),
164 dissolved in sunflower oil.

165

166 **2.5 Ex vivo embryonic mammary gland culture and 4D live-cell imaging**

- 167 1. Tissue Culture Dish with Cover Glass Bottom (35 mm).
- 168 2. Cell culture inserts (0.4 µm, 30 mm diameter; Millicell).
- 169 3. 10x Pancreatin solution pH 7.0: 2.5 g of pancreatin from porcine pancreas (Cat. #
170 P3292-25G, Sigma) and 0.85 g NaCl dissolved in 100 ml of cold MilliQ water and filter-
171 sterilised (for preparation guidelines See **Note 3**).
- 172 4. Porcine Trypsin, 1:250 (Cat. # 85450C-25G, SAFC).

- 173 5. Thyrode's solution (pH 7.4): 8 g/l NaCl, 0.2 g/l KCl, 0.05 g/l NaH₂PO₄ + H₂O, 1 g/l
174 glucose, 1 g/l NaHCO₃ dissolved in 1 litre of distilled water and filter sterilised.
175 6. Pancreatin-trypsin working solution pH 7.4: 0.225 g porcine trypsin made up in a final
176 volume of 10 ml Thyrode's solution containing 1 ml 10x pancreatin stock solution and
177 20 µl of PS. Filter sterilise before use (for preparation guidelines See **Note 4**).
178 7. Ascorbic acid: 10 mg/ml in distilled water and filter sterilised (Cat. # A4544-25G,
179 Sigma).
180 8. Horizontal laminar flow hood.
181 9. Inverted CLSM microscope (e.g. Zeiss LSM780/880) or two-photon confocal
182 microscope (e.g. Leica SP8 microscope with a Chameleon Vision II laser), equipped
183 with a heated environmental chamber.
184 10. Long-working distance objective (e.g. Zeiss 40x/1.0NA water immersion objective,
185 Leica 25x/0.95NA water immersion objective).
186 11. Image analysis software and processing tools: e.g. ImageJ (<https://imagej.nih.gov/ij/>),
187 Imaris (<http://www.bitplane.com/>).
188

189 **2.6 Enzymatic digestion and wholemount immunostaining of mammary tissues**

- 190 1. Enzyme digestion (ED) mix: HBSS containing 300 U/ml collagenase (Cat. # C0130,
191 Sigma) and 300 µg/ml hyaluronidase (Cat. # 4272, Sigma).
192 2. HBSS.
193 3. PBS.
194 4. 4% Paraformaldehyde in PBS.
195 5. NH₄Cl, 0.5 M.
196 6. ED Blocking buffer: 1% (w/v) bovine serum albumin (BSA), 5% (v/v) horse serum and
197 0.8% (w/v) Triton-X100 in PBS.
198 7. PBST: PBS + 0.2% (w/v) Tween20.
199 8. 4',6-diamidino-2-phenylindole (DAPI) dilactate.
200 9. Primary and fluorescent secondary antibodies (as required).
201 10. Microscope slides and coverslips (No. 1.5).
202 11. Aqua Poly/Mount.
203

204 **2.7 CUBIC-based optical tissue clearing**

- 205 1. 10% Neutral Buffered Formalin (NBF).
206 2. Card or glass microscope slides.
207 3. PBS.

- 208 4. CUBIC Reagent 1A: 10% (w/w) urea, 5% (w/w) N,N,N',N'-tetrakis(2-
209 hydroxypropyl)ethylenediamine, 10% (w/w) Triton-X100 and NaCl (25 mM) in distilled
210 water (See **Notes 5 and 6**).
- 211 5. CUBIC Reagent 2: 44% (w/w) sucrose, 22% (w/w) urea, 9% (w/w) 2,2',2''-
212 nitrilotriethanol and 0.1% (w/w) Triton-X100 in distilled water.
- 213 6. CUBIC Blocking buffer: 10% (v/v) goat serum, 0.5% (w/v) Triton-X100 in PBS.
- 214 7. 4',6-diamidino-2-phenylindole (DAPI) dilactate.
- 215 8. *Optional*: Primary and fluorescent secondary antibodies as necessary.
- 216 9. Glass bottomed imaging dishes (e.g. Cat # 81158, Ibidi).

217 **2.8 SeeDB-based optical tissue clearing**

- 218 1. 10% Neutral Buffered formalin (NBF).
- 219 2. Card or glass microscope slides.
- 220 3. PBS.
- 221 4. α -thioglycerol.
- 222 5. Serial fructose solutions made up in distilled water – 20%, 40%, 60%, 80%, 100%
223 (w/v), SeeDB (115% (w/v)) (see **Note 7**).
- 224 6. SeeDB Blocking buffer: 10% (w/v) bovine serum albumin (BSA), 1% (w/v) Triton-X100
225 in PBS.
- 226 7. 4',6-diamidino-2-phenylindole (DAPI) dilactate.
- 227 8. *Optional*: Primary and fluorescent secondary antibodies as necessary.
- 228 9. Glass bottomed imaging dishes (e.g. Cat # 81158, Ibidi).

229 **3. Methods**

230

231 **3.1 Mammary imaging window implantation for 4D-IVM**

232 All animal studies must be approved by institutional ethical committees and national authorities
233 as required. Perform surgeries according to the LASA Guiding Principles of Preparing and
234 Undertaking Aseptic Surgery to minimise infection risk (See **Note 8**). Due to its fast induction
235 and recovery, alongside the ability to precisely control anaesthesia depth and length,
236 inhalation anaesthetics should be used for window implantation and intravital imaging [14, 17].
237 While acute intravital imaging of the mammary gland under non-recovery anaesthesia (i.e.
238 where the animal is euthanised immediately at the end of imaging) can be performed via a
239 skin-flap incision [14, 38, 39], this approach poses challenges for maintaining optimal mouse
240 hydration and physiology. Thus, implanting a MIW is also beneficial when performing non-
241 recovery imaging studies spanning several hours. When applied to fluorescent reporter mouse
242 models, IVM is a powerful approach for tracing the fate, migration, proliferation, geometry and

243 re-arrangements of individual cells in real-time during mammary gland postnatal development
244 and tissue homeostasis.

245 3.1.1 Mammary imaging window (MIW) preparation

- 246 1. Apply a thin layer of cyanoacrylate-based glass glue on the etched inset of the MIW
247 that will contact the coverslip.
- 248 2. Using forceps, place the coverslip on the glue-covered inset and apply gentle pressure
249 using a cotton swab for 1 min. If necessary, apply glue at the interface of the coverslip
250 and the window.
- 251 3. Allow the glue to dry completely by placing it on its side in a flow cabinet for a minimum
252 of 2 h.
- 253 4. If required, use a cotton swab soaked in 100% acetone to remove excessive and
254 condensed glue from the coverslip. Use a cotton swab soaked in 70% (v/v) ethanol to
255 remove the acetone.
- 256 5. Place the window glass-side down on a dry tissue and fill with physiological saline to
257 assess for leaks. If the window is watertight, the tissue will remain dry (**See Note 9**).
- 258 6. Sterilise the MIW by steam sterilisation, or by placing it in 70% (v/v) ethanol for a
259 minimum of 30 min. Do not autoclave cover-slipped windows as it will degrade the
260 glue.
- 261 7. *Optional*: In a sterile flow cabinet, coat the interior side of the coverslip with PLL-g-
262 PEG solution. Incubate for 1 h at room temperature. Subsequently, wash the window
263 in sterile PBS (**See Note 10**).

264 3.1.2 Surgery preparation

- 265 1. Sterilise surgical tools by autoclaving or dry sterilization (**See Note 11**). Thoroughly
266 disinfect the entire operating station (including heat-pads, anaesthesia nose cones and
267 adjustment controls) using 70% ethanol.
- 268 2. Anaesthetise the mouse in an induction chamber using 3-4% (v/v) gaseous isoflurane
269 (**See Note 12**).
- 270 3. Once anaesthetised, transfer the mouse onto a heat-pad situated away from the sterile
271 operating area, and continue to supply anaesthesia via a nose cone. Reduce the
272 isoflurane concentration to 1.5-2% (v/v) (**See Note 13**).
- 273 4. Apply ophthalmic ointment to both eyes to prevent corneal drying.
- 274 5. Administer Buprenorphine at a dose of 0.1 mg/kg mouse body weight by sub-
275 cutaneous injection (**See Note 14**).
- 276 6. Shave the skin over the 4th mammary gland using electronic pet clippers. As stray hairs
277 under the window pose an infection risk and can obstruct imaging, it is important to

- 278 remove as much residual hairs as possible from the surgical field. Brief exposures to
279 depilatory cream can be used if necessary.
- 280 7. Disinfect the shaved skin using Betadine solution and a cotton gauze. Begin at the
281 centre of the surgical site and move out towards the periphery using an ever-widening
282 circular motion. Repeat 3 times using a clean gauze each time.
 - 283 8. Gently transfer the mouse to the disinfected heated operating stage. Continue to
284 supply the mouse with 1.5-2% (v/v) isoflurane via a nose cone to maintain anaesthesia.
 - 285 9. Loosely immobilise the hind legs using tape. Cover the mouse with a sterile surgical
286 drape equipped with an opening to allow access to the prepared surgical field.

287 3.1.3 *Surgical implantation of the MIW*

- 288 1. Verify that the mouse is sufficiently anaesthetised by pinching a hind paw through the
289 overlying sterile drape. If the mouse is unresponsive, proceed to the next step.
290 Otherwise, adjust the isoflurane dose and wait until reflex behaviours are absent.
- 291 2. Use sterile forceps to gently lift the skin away from the abdominal wall and make a ~12
292 mm long incision in the flank area above the 4th abdominal mammary gland using
293 sterile scissors (Fig. 1a, panel 1. See **Notes 15 and 16**).
- 294 3. Use sterile forceps to blunt dissect the skin away from the underlying mammary gland,
295 taking care not to damage the tissue.
- 296 4. Place a circular purse-string suture around the incision, approximately 4 mm from skin
297 edges. Keep the external sections of the suture loose at this stage, leaving 4 butterfly-
298 wing shaped outer loops (Fig. 1a, panel 2).
- 299 5. Using forceps, carefully insert the window on the exposed mammary gland and gently
300 place the sutured skin into the window groove (Fig. 1a, panel 3).
- 301 6. Carefully pull the loops of the purse-string to tighten the skin in the window groove,
302 securing it in place (Fig. 1a, panel 3). Place a double knot to fix the purse-string suture,
303 making sure to hide the knot underneath the upper ring of the window to prevent the
304 mice from biting it open (Fig. 1b).
- 305 7. Proceed immediately to intravital imaging (Subheading 3.2), or allow the mouse to
306 recover from the anaesthesia in a cage placed on a heating pad at 37 °C. Once
307 recovered, the mouse may be group-housed with other window-bearing mice.
- 308 8. Post-operative care: Closely monitor mice for signs of pain and discomfort after
309 surgery. If required, provide post-operative analgesics in accordance with local
310 veterinary guidance (See **Note 17**). Inspect the surrounding skin and the tissue
311 underneath the MIW daily for signs of inflammation and necrosis.

312 **3.2 Longitudinal 4D-IVM by multiphoton microscopy**

- 313 1. If not proceeding directly from MIW surgery (Subheading 3.1), anaesthetise the mouse
314 in an induction chamber using 3-4% (v/v) gaseous isoflurane.
- 315 2. *Optional*: administer fluorescent probes by tail vein injection to label mammary cells
316 and structures as necessary (**see Note 18**).
- 317 3. To maintain mouse hydration during short-term experiments (< 3 h), administer a
318 maximum of 500 µl saline by sub-cutaneous injection prior to imaging. In experiments
319 exceeding 3 h, saline should be provided periodically (~ 50–100 µl/hour) using an
320 indwelling intraperitoneal line [14, 17] (**See Note 19**).
- 321 4. Transfer the mouse onto the stage insert of a multiphoton microscope for imaging,
322 continuing to supply 1.5-2% (v/v) isoflurane via a nose cone to maintain anaesthesia.
- 323 5. Position and immobilise the MIW for imaging. On an inverted set-up, a microscope
324 insert or box customised with a hole that precisely fits the window can be used for
325 stabilisation [19]. To image in the upright configuration, the window can be fixed using
326 custom-made holders or microstage devices [38] (**See Note 20**). Maintain the mouse's
327 body temperature at 37 °C during imaging, ideally using a dark heated chamber that
328 surrounds the microscope stage.
- 329 6. Once the mouse is secure and stabilised, reduce the isoflurane concentration to
330 between 0.8%-1.2% (**See Note 21**).
- 331 7. Closely monitor the mouse's vital parameters during imaging:
 - 332 a) Regularly check the breathing rate and adjust the isoflurane supply
333 accordingly if irregular or abnormal breathing is observed.
 - 334 b) Measure the mouse's temperature during imaging using a rectal probe.
335 Adjust the temperature of the heated imaging chamber as necessary.
 - 336 c) Monitor capillary blood flow to ensure optimal conditions for imaging.
 - 337 d) Continuous assessment of vital parameters can be performed using a non-
338 invasive pulse oximetry monitoring system (e.g. MouseOx system) that measures the
339 mouse's temperature, arterial oxygen saturation, breathing distension, and heart and
340 respiratory rates during imaging.
- 341 8. When anaesthesia levels are tightly controlled and animal vitals well-maintained, 4D-
342 IVM can be performed continuously for up to ~40 h under non-recovery anaesthesia
343 [39]. Alternatively, longitudinal IVM can be performed whereby mice undergo repeated,
344 shorter imaging sessions over extended periods of time (**See Note 22**).
- 345 9. For longitudinal imaging of specific cells and tissue structures, a number of approaches
346 can be used to help retrace regions of interest in consecutive imaging sessions,
347 including:

- 348 a) Using a motorized stage: In configurations where the relative position of the
349 imaging window is fixed in repeated imaging sessions, the coordinates of individual
350 regions can be stored and used to relocate imaging areas.
- 351 b) Morphological landmarks: the branched mammary epithelial network is structurally
352 heterogeneous, providing unique patterns of ductal structures and adjacent blood
353 vessels that can be readily recognised in repeat imaging sessions though the
354 eyepiece or by manual scanning (See **Note 23**). Intravenous injection of
355 fluorescent agents to label vasculature (e.g. fluorescently-labelled dextrans), in
356 addition to second harmonic generation (SHG) imaging of tissue collagen
357 organisation, can also assist with retracing regions of interest in consecutive
358 imaging sessions (Fig. 1c).
- 359 c) Fluorescent reporter mouse models: Heterogeneous labelling of mammary
360 epithelial cells gives rise to unique and identifiable colour patterns for serial imaging
361 e.g. using fluorescent reporter mouse models such as *R26R-Confetti* [9, 40] or
362 *Rosa26-mTmG* [37] mouse strains (Fig. 1c).
- 363 10. *Optional*: To aid the re-identification of intravitaly imaged mammary tissue regions in
364 downstream 3D or 2D histological analyses, at the end of the final imaging session use
365 focused high laser power to generate distinct auto-fluorescent “photo-tattoos” in
366 nearby tissue areas, taking care not to damage cells and tissue structures of interest
367 [41].
- 368 11. At experimental endpoints, euthanise the mouse according to institutional/national
369 guidelines.
- 370 12. Taking note of the orientation of the tissue relative to the coverslip, harvest and fix the
371 intravitaly imaged mammary gland for downstream histological analysis (e.g. by 3D
372 wholemount immunostaining as described in Subheading 3.5). Harvest the contra-
373 lateral, non-window mammary gland as a control.
- 374 13. To reuse the MIW, clean the titanium ring using soap and hot water. Incubate overnight
375 in 100% acetone to remove the glue and release the used coverslip. Prepare the MIW
376 for future implantation following the instructions detailed in Subheading 3.1.1.
- 377 14. Process and analyse intravital images using ImageJ (<https://imagej.nih.gov/ij/>) and/or
378 commercial software such as Imaris (<http://www.bitplane.com/>), depending on
379 availability.
- 380

381 **3.3 Establishing mammary embryonic buds in culture for 4D ex vivo imaging**

382 The mammary epithelium is first specified as placodes at approximately embryonic (E) day
383 11, which invaginate into the underlying mesenchyme to form mammary buds by E12. After

384 E15.5, buds undergo sprouting and branching morphogenesis to give rise to a rudimentary
385 epithelial tree by E18.5 [42]. To visualise this process in real-time, mammary embryonic buds
386 must be established in *ex vivo* culture [21–23]. In this section, we describe methods for high-
387 resolution longitudinal or time-lapse fluorescence imaging of *ex vivo* cultured embryonic
388 mammary buds by CLSM and multiphoton microscopy. Similarly to IVM, when applied to
389 fluorescent reporter mouse models this approach allows for the dynamic behaviour and fate
390 of individual embryonic mammary cells to be traced in real-time during embryonic mammary
391 morphogenesis.

392 3.3.1 Dissection of the embryonic mammary gland

- 393 1. Set up timed mouse matings to obtain pregnant females bearing embryos of the
394 desired genotype and age. Embryo stage is determined by the detection of a vaginal
395 plug the following day (detection at mid-day defined as 0.5 days-post-coitus i.e. E0.5).
- 396 2. *Optional*: If using Cre-inducible fluorescent reporter mice, administer a low dose of
397 tamoxifen to pregnant females 24 h before tissue dissection to induce fluorescent
398 labelling in embryos. While a tamoxifen dose of 0.1 mg/g of mouse body weight is
399 commonly used, precise doses will vary depending on specific study requirements
400 [26].
- 401 3. At the desired embryonic stage, sacrifice the pregnant female and harvest the embryos
402 from the uterus in a 100 mm diameter Petri dish filled with cold PBS.
- 403 4. Remove the yolk sac and separate each embryo from its placenta, taking care not to
404 damage the tissue (Fig. 2, panel 1).
- 405 5. Sacrifice each embryo by decapitation and place in separate wells of a 24 well plate
406 filled with cold PBS. Keep tissues to confirm genotypes and sex by PCR (see **Note**
407 **24**).
- 408 6. Place one embryo in a 35 mm culture dish filled with set silicon. Secure the embryo in
409 place by pinning the neck and tail joint using needles or dissection pins (Fig. 2, panel
410 2).
- 411 7. Remove the limbs. This makes the 1st and 5th mammary buds accessible for dissection
412 (Fig. 2, panel 3).
- 413 8. Perform a small incision above the tail joint of the embryo. Using spring scissors, cut
414 along the dorsal-lateral line from the hind limb to the forelimb in the right flank of the
415 embryo (Fig. 2, panel 4).
- 416 9. Detach the flank of the embryo from the incision along the dorsal-lateral line to the
417 midline (Fig. 2, panel 5). Hold the tissue using Dumont #5 forceps, and use the spring
418 scissors to trim the right flank (see **Note 25**).

- 419 10. Repeat step 8 and 9 with the left flank of the embryo, but this time cutting along the
420 dorsal-lateral line from the forelimb to the hind limb.
421 11. Transfer both flanks to a new 24 well plate with PBS (Fig. 2, panel 6).
422

423 3.3.2 *Separating the embryonic skin epithelium and mesenchyme*

424 This procedure entails proteolytic digestion of dissected embryonic flanks, based on a
425 protocol developed by the laboratory of M. Mikkola [23].

- 426 1. Replace the PBS with pancreatic-trypsin working solution (see Materials 2.5) and
427 incubate for 4-5 min. Optimal incubation times are heavily dependent on embryo stage,
428 in addition to the particular enzyme batches used [23]. Thus, closely monitor the tissue
429 under the stereomicroscope during enzyme treatment.
- 430 2. When the skin epithelium starts to detach from the edges of the mammary
431 mesenchyme, inactivate the enzymes by replacing the pancreatic-trypsin solution with
432 DMEM/F-12 embryonic culture medium (see Materials 2.4 and **Note 26**).
- 433 3. Incubate the mammary tissue on ice for 30-45 min.
- 434 4. Place the mammary tissue in a 35 mm culture dish. Using two needles, gently peel the
435 skin epidermis away from the mesenchyme containing the embryonic mammary buds.
436 The mesenchyme is required for embryonic mammary epithelial development [21] and
437 should be maintained as intact as possible around mammary buds (Fig. 2, panel 7).
- 438 5. Once isolated, use a plastic pipette to transfer the intact mesenchyme containing the
439 embryonic mammary buds to fresh DMEM/F-12 embryonic culture medium in a 24 well
440 plate. Repeat this process for all harvested tissues.

441

442 3.3.3 *Establishing mammary buds in ex vivo culture*

- 443 1. Per embryo, prepare a 35 mm cover glass-bottomed tissue culture dish containing 1
444 ml of DMEM/F-12 embryonic culture medium (see Materials 2.4) freshly supplemented
445 with 75 µg/ml ascorbic acid.
- 446 2. Place the embryonic mammary tissue on a cell culture insert (containing 0.4 µm pores)
447 using a 1000 µl pipette.
- 448 3. Using curved micro-dissecting forceps, carefully and slowly place the cell culture insert
449 into the prepared glass-bottomed tissue culture dish to avoid bubble formation. This
450 ensures mammary embryonic buds are cultured on an air-liquid interface, whereby the
451 tissue remains exposed to air while maintaining contact with the embryonic cell culture
452 medium through the pores of the cell culture insert (Fig. 2, panel 8).
- 453 4. Maintain mammary cultures in a tissue culture incubator at 37 °C and 5% CO₂
454 atmosphere.

455 5. Exchange the culture media with fresh media every second day for the duration of the
456 experiment. Cultures can be maintained *ex vivo* for up to 2 weeks.

457

458 **3.4 4D time-lapse and longitudinal imaging of *ex vivo* embryonic mammary cultures**

459 Once established in *ex vivo* culture, embryonic mammary branching development can be
460 recorded daily by 3D fluorescence imaging for up to 2 weeks. Use an inverted CLSM or
461 multiphoton microscope (e.g. Zeiss LSM780/880 or Leica SP8) equipped with long-working
462 distance objectives to acquire high-resolution 3D image stacks at each time-point (Fig. 3a).
463 Alternatively, time-lapse imaging can be performed for up to 24 hours (Fig. 3b). Below, we
464 provide an overview of the experimental conditions that facilitate high-resolution, *ex vivo*
465 imaging of fluorescently labelled embryonic mammary epithelial cells over time.

466

467 1. Isolate embryonic mammary buds from a fluorescent reporter mouse model and
468 establish in *ex vivo* culture as described in sub-heading 3.3. Fig. 3a and 3b show a
469 cultured embryonic mammary bud established from a *Lgr5-GFP* [36] or *Rosa26-*
470 *mTmG* [37] reporter mouse embryo respectively. In the absence of Cre-mediated
471 recombination in the *Rosa26-mTmG* mammary bud (Fig. 3b), all embryonic mammary
472 epithelial and stromal cells are labelled with a membrane-bound Tomato fluorescent
473 protein.

474 2. Due to superior depth of imaging and low photo-toxicity, a multiphoton confocal
475 microscope is preferred for time-lapse imaging of *ex vivo* embryonic mammary cultures
476 e.g. an inverted Leica SP8 microscope equipped with a femtosecond Chameleon
477 Vision II multiphoton laser (680–1350 nm; Coherent, Inc.) and long-working distance
478 objectives (e.g. Leica 25×/0.95NA water immersion objective).

479 3. The microscope should be equipped with an incubation chamber that maintains tissues
480 at 37 °C, 5% CO₂ atmosphere and 95% humidity (**see Note 27**). To avoid sample drift
481 in the Z-axis, allow environmental conditions of the microscope chamber to stabilise
482 for 30-60 min before commencing image acquisition.

483 4. Acquire image sequences as Z-stacks of the desired volume. Image acquisition time
484 may vary between 30-60 min, depending on tissue thickness and area imaged, as well
485 as the number of fluorophores to detect.

486 5. To image the whole embryonic mammary epithelium, overview tile scans can be
487 acquired. Ensure at least a 10% overlap between tiled images, which can be stitched
488 into larger mosaics using the microscope's acquisition software, or ImageJ Plugins
489 (e.g. the Grid Collection/Stitching plugin) (<https://imagej.nih.gov/ij/>).

490 6. Time-lapse processing and analysis can be performed using ImageJ and/or
491 commercial software such as Imaris (<http://www.bitplane.com/>), depending on
492 availability.

493

494 **3.5 3D fluorescence imaging of fixed mammary gland tissues**

495 In this section, we provide three protocols for wholemount immunostaining and 3D
496 visualisation of fixed mammary gland tissues, encompassing proteolytic digestion and two
497 optical tissue clearing methods, namely CUBIC [29] and SeeDB [28]. These can be applied to
498 freshly harvested tissues, or after completing 4D *in vivo/ex vivo* imaging to further characterise
499 live-imaged tissue regions by immunostaining. While proteolytic-digestion methods are
500 particularly useful for whole-gland imaging of immunostained mammary tissues [24–27],
501 CUBIC and SeeDB optical tissue clearing methods facilitate visualisation of the mammary
502 epithelial tree at single-cell resolutions within its intact stroma [11, 30–34] (see **Note 28**). For
503 an overview of the optical tissue clearing methods previously applied to the mammary gland,
504 in addition to their advantages and disadvantages, see [2, 11].

505

506 **3.5.1 Proteolytic digestion-based immunostaining of mammary gland tissues**

- 507 1. Euthanise mice according to institutional/national guidelines.
- 508 2. Excise mammary glands and immerse in Enzyme Digestion solution (see Materials
509 2.6) for 30–60 min (depending on tissue size) at 37 °C with gentle agitation. Due to its
510 small size, high quality wholemount immunostaining can be performed in embryonic
511 mammary gland tissues and explants without the need for enzymatic digestion [43]
512 (Fig. 4).
- 513 3. Wash tissues 3 times in HBSS (5 min each time).
- 514 4. Fix tissues for 2 h at room temperature in 4% PFA.
- 515 5. Wash samples twice in 0.5 M NH₄Cl (10 min each time).
- 516 6. Wash tissues 3 times in PBS (10 min each time).
- 517 7. Incubate tissues in ED blocking buffer (see Materials 2.6) for 3 h at room temperature,
518 or overnight at 4 °C with gentle agitation.
- 519 8. Incubate samples in primary antibodies diluted in blocking buffer overnight at room
520 temperature.
- 521 9. Wash samples three times in PBST (10 min each time).
- 522 10. Incubate samples with secondary antibodies diluted in blocking buffer for 5 h at room
523 temperature, or overnight at 4 °C with gentle agitation.
- 524 11. Wash samples three times in PBST (10 min each time).

- 525 12. Incubate tissues with DAPI (10 μ M) for 30 min to 1 h at room temperature with gentle
526 agitation to stain nuclei.
- 527 13. Mount tissues on microscope slides using Aqua Poly/Mount, taking care to avoid
528 bubbles.
- 529 14. Acquire images using CLSM (e.g. Zeiss LSM780/880 or Leica SP8) with a long-
530 working distance objective to facilitate deep tissue imaging (e.g. Zeiss 25x/0.8 oil
531 immersion objective or Leica 25x/0.95NA water immersion objective).
- 532 15. Imaging considerations: Adjust laser power and gain manually to give optimal
533 fluorescence intensity for each fluorophore with minimal photobleaching. Acquire Z-
534 stacks using step-sizes and line averaging appropriate for the desired resolution. If
535 performing tile-scans, at least a 10% overlap is recommended for optimal stitching of
536 tiled images into larger mosaics (Fig. 4). Stitching can be performed using the
537 microscope's acquisition software, or using ImageJ Plugins (e.g. the Grid
538 Collection/Stitching plugin) (<https://imagej.nih.gov/ij/>).
- 539 16. Process and analyse image stacks using ImageJ (<https://imagej.nih.gov/ij/>) and/or
540 commercial software such as Imaris (<http://www.bitplane.com/>) depending on
541 availability.

542

543 3.5.2 Modified CUBIC tissue clearing and immunostaining of mammary gland tissues

- 544 1. Euthanise mice according to institutional/national guidelines.
- 545 2. Excise mammary glands and spread immediately on card (Tetra Pak) or glass
546 microscope slides (see **Note 29**).
- 547 3. Fix tissues by immersing in 10% NBF for 6-9 h (according to tissue size/thickness) at
548 room temperature (see **Note 30**).
- 549 4. Wash tissues briefly in PBS with gentle agitation to remove residual NBF. Cut tissues
550 into large (~15×15×2 mm) pieces if necessary (see **Note 31**).
- 551 5. Immerse tissues in modified CUBIC Reagent 1A (see Materials 2.7) at 37 °C for 2-3
552 days, depending on the size of the tissue, exchanging the solution with fresh R1A each
553 day. For timeline, see Fig. 5a.
- 554 6. Wash samples 3 times in PBS (10 min each time) to remove excess R1A solution. If
555 tissues are to be imaged for genetically-encoded fluorescent proteins and do not
556 require immunostaining, proceed to step 12.
- 557 7. *Optional immunostaining*: Immerse tissues in CUBIC blocking buffer (see Materials
558 2.7) and incubate overnight at 4 °C with gentle agitation.
- 559 8. Incubate tissues with primary antibodies diluted in CUBIC blocking buffer at 4°C for 4
560 days with gentle agitation. Incubation times may be optimised for specific antibodies.

- 561 9. Wash tissues 3 times in PBS (1 h each time) with gentle agitation at room temperature.
562 10. Incubate samples with Alexa Fluor-conjugated secondary antibodies made up in PBS
563 for 2 days at 4°C with gentle agitation (see **Note 32**).
564 11. Wash tissues 3 times in PBS (1 h each time) with gentle agitation at room temperature.
565 12. Incubate with DAPI (10 µM) for 2-3 h at room temperature with gentle agitation.
566 13. Transfer samples to CUBIC Reagent 2 (see Materials 2.7) and incubate at 37°C for at
567 least 24 h for refractive index matching before imaging (Fig. 5b).
568 14. Image samples in CUBIC Reagent 2 by CLSM or multiphoton microscopy within 1
569 week (e.g. Zeiss LSM780/880 or Leica SP8 equipped with long-working distance
570 objectives to facilitate deep tissue imaging). Samples may be imaged on inverted
571 microscopes using glass-bottomed iBidi dishes, or mounted in CUBIC Reagent 2 for
572 imaging (Fig. 5c) (see **Note 33**).
573 15. Imaging considerations: adjust laser power and gain manually to give optimal
574 fluorescence intensity for each fluorophore with minimal photobleaching. Acquire Z-
575 stacks using step-sizes and line averaging appropriate for the desired resolution. If
576 performing tile-scans, at least a 10% overlap is recommended for optimal stitching of
577 tiled images into larger mosaics. Stitching can be performed using the microscope's
578 acquisition software, or using ImageJ Plugins (e.g. the Grid Collection/Stitching plugin)
579 (<https://imagej.nih.gov/ij/>).
580 16. If tissues were previously imaging by 4D intravital imaging, place cleared samples in
581 the same orientation for imaging. To re-trace regions of interest, some of the strategies
582 suggested for longitudinal IVM may be used (see Subheading 3.2, Step 9) e.g. using
583 morphological landmarks or laser-induced autofluorescent photo-tattoos.
584 17. Process and analyse image stacks using ImageJ (<https://imagej.nih.gov/ij/>) and/or
585 commercial software such as Imaris (<http://www.bitplane.com/>) depending on
586 availability.

587

588 3.5.3 SeeDB tissue clearing and immunostaining of mammary gland tissues

- 589 1. Euthanise mice according to institutional/national guidelines.
590 2. Excise mammary glands and spread immediately on card (Tetra Pak) or glass slides
591 (see **Note 29**).
592 3. Fix tissues by immersing in 10% neutral buffered formalin (NBF) for 6-9 h (according
593 to tissue size/thickness) at room temperature (see **Note 30**).
594 4. Subsequently, wash tissues briefly in PBS with gentle agitation to remove residual
595 NBF. Cut tissues into large (~15×15×2 mm) pieces if necessary (see **Note 31**).
596 5. If tissues are to be imaged for genetically-encoded fluorescent proteins and do not
597 require immunostaining, proceed to step 11. For timeline, see Fig. 6a.

- 598 6. *Optional immunostaining*: Immerse tissues in SeeDB blocking buffer (see Materials
599 2.8) overnight at 4°C with gentle agitation.
- 600 7. Incubate tissues with primary antibodies diluted in SeeDB blocking buffer at 4°C for 4
601 days with gentle agitation. Incubation times may be optimised for specific antibodies.
- 602 8. Wash tissues 3 times in PBS (1 h each time) with gentle agitation at room temperature.
- 603 9. Incubate samples with Alexa Fluor-conjugated secondary antibodies made up in PBS
604 for 2 days at 4°C with gentle agitation.
- 605 10. Wash tissues 3 times in PBS (1 h each time) with gentle agitation at room temperature.
- 606 11. Incubate with DAPI (10 µM) for 2-3 h at room temperature with gentle agitation.
- 607 12. Subsequently, serially incubate samples for 8-16 h (twice daily changes i.e. at
608 beginning and end of the day) at room temperature with gentle agitation in increasing
609 fructose solutions: 20%, 40%, 60% and 80% (w/v) fructose solutions containing freshly
610 added 0.5% (v/v) α-thioglycerol to inhibit the Maillard reaction [28].
- 611 13. Incubate samples in 100% (w/v) fructose solution containing freshly added 0.5% (v/v)
612 α-thioglycerol for 24 h at room temperature.
- 613 14. Incubate samples in SeeDB (115% (w/v)) fructose solution containing freshly added
614 0.5% (v/v) α-thioglycerol for 24 h at room temperature before imaging (Fig. 6b).
- 615 15. Image samples in SeeDB reagent by CLSM or multiphoton microscopy within 2 weeks
616 (e.g. Zeiss LSM780/880 or Leica SP8 equipped with long-working distance objectives
617 to ensure deep tissue imaging). Samples may be imaged on inverted microscopes
618 using glass-bottomed iBidi dishes, or mounted in SeeDB reagent for imaging (Fig. 6c)
619 (see **Note 33**).
- 620 16. Imaging considerations: adjust laser power and gain manually to give optimal
621 fluorescence intensity for each fluorophore with minimal photobleaching. Acquire Z-
622 stacks using step-sizes and line averaging appropriate for the desired resolution. If
623 performing tile-scans, at least a 10% overlap is recommended for optimal stitching of
624 tiled images into larger mosaics. Stitching can be performed using the microscope's
625 acquisition software, or using ImageJ Plugins (e.g. the Grid Collection/Stitching plugin)
626 (<https://imagej.nih.gov/ij/>).
- 627 17. If tissues were previously imaging by 4D intravital imaging, place cleared samples in
628 the same orientation for imaging. To re-trace regions of interest, some of the strategies
629 suggested for serial IVM may be used (see Subheading 3.2, Step 9) e.g. using
630 morphological landmarks or laser-induced autofluorescent photo-tattoos.
- 631 18. Process and analyse Z-stack images using ImageJ (<https://imagej.nih.gov/ij/>) and/or
632 commercial software such as Imaris (<http://www.bitplane.com/>) depending on
633 availability.
- 634

635 **4. Notes**

- 636 1. This protocol describes a re-usable titanium MIW that is based on the design of the
637 abdominal imaging window [17, 19, 20]. This consists of an upper and a lower titanium
638 ring (outer diameter 14 mm), separated by a 0.9 mm width groove. Titanium possesses
639 superior biocompatibility compared to other stainless alloys.
- 640 2. Suture material may depend on user preference. Non-absorbable 5-0 nylon and 6-0
641 silk sutures is also used for imaging window implantation.
- 642 3. Dissolve pancreatin from porcine pancreas and NaCl in MilliQ water using a magnetic
643 stirrer on ice for 3-4 h (or at 4 °C overnight). Centrifuge 5000 rpm for 10 min and filter
644 using suction prior to use.
- 645 4. Dissolve 0.225 g porcine trypsin in 6 ml of ice-cold Thyrode's solution using a magnetic
646 stirrer on ice. Once in solution add 1 ml of 10x pancreatin stock solution, in addition to
647 20 µl of PS. Using NaOH, adjust the pH of the solution to 7.4. Make up the solution to
648 a final volume of 10 ml using additional ice-cold Thyrode's solution. Filter and prepare
649 single-use aliquots.
- 650 5. CUBIC Reagent 1A is a modified, unpublished version of CUBIC Reagent 1 [29]
651 available at <http://cubic.riken.jp/>. CUBIC reagents require heat (60 °C) and agitation to
652 dissolve.
- 653 6. N,N,N',N'-tetrakis(2-hydroxypropyl)ethylenediamine is highly viscous. Dispense this
654 reagent first and adjust other reagent amounts accordingly. In the original protocol [29],
655 the authors state that a specific brand of Triton X-100 (Nacalai Tesque Inc., 25987-85,
656 Japan) is required to avoid quenching endogenous EGFP fluorescence. However, in
657 our hands, Triton X-100 purchased from VWR International is compatible with EGFP
658 fluorescent protein in 10% NBF-fixed mammary gland tissues. If quenching is
659 suspected, consider immunostaining tissues with a GFP antibody, or use an alternative
660 optical tissue clearing method [2, 44].
- 661 7. Fructose solutions greater than 60% are difficult to get into solution. Use heat (60 °C)
662 and agitation to dissolve.
- 663 8. To avoid contaminating the surgical station, prepare the mouse for surgery in a
664 separate area before transferring to the sterilised operating station. Autoclaved tools
665 should only come into contact with sterile gloves, surfaces and the disinfected skin
666 area undergoing surgery. To safeguard sterility throughout the procedure, the surgeon
667 should only contact sterile tools and the prepared surgical field. Mouse preparation
668 and handling, adjustment of anaesthesia flow rates and similar tasks should be
669 performed by an assistant.
- 670 9. For optimal results, it is essential that the seal between the titanium ring and coverslip
671 is air and watertight.

- 672 10. PEG-based coating of the glass coverslip can be performed to prevent cell attachment
673 and to improve its biocompatibility, limiting the risk of an inflammatory or immune
674 reaction in response to implantation.
- 675 11. Ideally, a new set of sterilised tools should be used per mouse. If this is unfeasible, a
676 bead sterilizer may be used to sterilise tools between limited numbers of mice.
- 677 12. Isoflurane - which requires oxygen as a carrier gas - is a well-tolerated inhalation
678 anaesthetic with minimal side-effects and a short recovery time. Isoflurane induction
679 and maintenance doses may require optimisation depending on animal parameters
680 (including strain, age and condition) and the available set up. It is advisable to use
681 relatively high doses of isoflurane for rapid induction (up to 4%), reducing doses to
682 maintenance levels as quickly as possible to minimise the time exposed to high
683 concentrations [14]. Isoflurane should be handled in well ventilated areas using
684 systems equipped with a gas scavenger to minimise user exposure to exiting gases.
- 685 13. Maintaining the physiological body temperature of the mouse is critical for long-term
686 survival under anaesthesia. This can be achieved using adjustable heated anaesthesia
687 posts and induction boxes, heat-pads or environmental chambers during intravital
688 imaging. Conversely, hyperthermia may amplify the effect of the inhalation
689 anaesthetic, depressing respiration rates. Monitor the mouse's body temperature
690 throughout surgery and intravital imaging using a rectal probe.
- 691 14. Buprenorphine may cause mild respiratory depression. Multi-modal regimes consisting
692 of Buprenorphine and a NSAID (e.g. Carprofen at a 5 mg/kg) may be recommended
693 by your local veterinarian. However, depending on the nature of the study, suppression
694 of the immune system by NSAIDs may impact important experimental parameters.
- 695 15. Gently handle the skin at incision edges when using forceps to avoid compression-
696 associated damage. Consider using non-serrated forceps to minimise this risk. For
697 optimal implantation, the incision size should closely match the size of the window.
- 698 16. While the MIW can be implanted over inguinal (3rd) mammary glands, the 4th is less
699 impacted by respiratory movements during imaging.
- 700 17. Post-operative buprenorphine (0.1 mg/kg for up to 3 days) may be administered to
701 provide additional pain relief. NSAIDs (e.g. Carprofen at a 5 mg/kg dose and/or
702 ibuprofen administered in drinking water) may also be used if appropriate (see Note
703 14). Local application of a topical analgesic (e.g. 1% Xylocaine) at the surgical site can
704 be used to provide additional pain relief [17].
- 705 18. Endogenous and injectable fluorescent probes may be used to study aspects of
706 mammary gland/tumour cell biology and tissue morphology [10, 45]. For example,
707 blood vessels can be labelled by injecting fluorescently-conjugated dextrans into the
708 circulation to investigate vascular flow and permeability, in addition to the invasion of

709 mammary tumourigenic cells into nearby vessels. Vessel labelling can also aid
710 identification of imaging regions in repeated IVM sessions, in addition to the
711 registration of serially acquired image stacks.

712 19. A winged infusion set attached to a syringe can be used to administer saline during
713 imaging. This can be performed manually, or by using a programmable syringe pump
714 for controlled, continuous administration.

715 20. An inverted microscope is preferable as it provides better stabilisation, reducing image
716 distortions arising from respiration-induced tissue movement. It is important not to
717 compress the underlying tissue and impair blood flow when immobilising the MIW.

718 21. These anaesthesia levels are optimal for long-term maintenance of mice in a
719 nonresponsive state with a constant and non-forced breathing pattern. Irregular and
720 abnormal breathing patterns are associated with persistent anaesthesia greater than
721 1.5%, which can decrease survival times [14, 39].

722 22. Due to the limited tolerance of mice to repeated anaesthesia, the duration and
723 frequency of imaging sessions in longitudinal experiments should be adapted
724 according to the study parameters under investigation, and in line with
725 institutional/national ethical rules. For instance, if mice are to be anaesthetised daily
726 for imaging, this should be restricted to shorter study time periods, with imaging
727 sessions kept as brief as possible to aid recovery.

728 23. Generating a tile scan of the imaging field using a low-magnification objective also aids
729 retracing of mammary regions of interest.

730 24. Before E14, there are no obvious morphological differences between female and male
731 mammary embryonic buds. To distinguish the embryos' sex, perform a PCR using the
732 following primer sequences and cycling conditions:
733 5'-TGGATGGTGTGGCCAATG-3', 3'-CACCTGCACGTTGCCCTT-5'
734 94 °C for 2 min; then 35 cycles of: 94 °C for 30 sec, 58 °C for 30 sec, 72 °C for 30 sec;
735 finally 72 °C for 5 min.
736 Run PCR products on a 2% agarose gel. One band is observed for female embryos
737 and two bands for male embryos.

738 25. Avoid cutting the tissue into small pieces as this will make the next steps challenging.

739 26. To exchange the medium hereafter, use pipette tips with narrow orifices (e.g. gel
740 loading tips) to carefully remove the medium without contacting mammary tissues.

741 27. Humidified conditions are required to minimise evaporation of the culture medium
742 during imaging.

743 28. Of a number of tissue clearing techniques tested in the mammary gland, SeeDB and
744 CUBIC protocols provided optimal results [11]. These protocols have subsequently
745 been further developed [46, 47], although they have yet to be tested in mammary

746 tissues. In the event of issues with penetration and staining performance of some
747 antibodies, other tissue clearing protocols are available [44], including FUnGI, a
748 method recently developed for the mammary gland [48].

749 29. Well-spread tissues are thinner and easier to render transparent. Fibres from
750 card/paper can transfer to tissues after fixation, hampering imaging from that side.
751 Using Tetra Pack card (e.g. milk carton card) overcomes this issue. Alternatively, foam
752 biopsy pads may be used.

753 30. Fixation time depends on the thickness and size of tissues, and may require antibody-
754 specific optimisation. Thinner or smaller tissue pieces and embryonic tissues may be
755 fixed after only 2-3 h at room temperature. A ~10:1 ratio v/v of NBF to tissue is required
756 for adequate fixation. Alternatively, fresh solutions of 4% PFA (for 2-4 h at room
757 temperature) may be used. In our hands, 10% NBF is compatible with several
758 genetically-encoded fluorescent proteins, including TdTomato, EGFP, YFP, RFP and
759 CFP in *Rosa26-mTmG*, *R26R-Confetti* and *Rosa26-tdTomato* reporter mouse strains
760 [11, 30, 31]. If quenching of fluorescent proteins is suspected, consider using
761 methanol-free Formaldehyde solutions.

762 31. While best to process samples immediately after harvesting, fixed tissues can be
763 stored at 4°C in PBS containing 0.05% (w/v) sodium azide for up to 8 weeks. Cutting
764 samples into large pieces may improve antibody penetration and immunostaining, in
765 addition to allowing more immunostainings to be performed in tissues harvested from
766 the same mouse.

767 32. CUBIC clearing is also compatible with wholemount immunohistochemistry using
768 HRP-conjugated secondary antibodies and horseradish peroxidase-3,3-
769 diaminobenzidine detection, in addition to the detection of β -glucosidase expression
770 (a magenta histochemical stain) (see [11, 30]).

771 33. Tissues may be mounted between coverslips using iSpacer chambers or concave
772 glass microscope slides. However, in these contexts, samples can be difficult to adjust
773 or repositioned for optimal illumination, making working distance a limiting factor in
774 image acquisition [11]. To mitigate this, sample thickness must be closely matched to
775 the thickness of the iSpacer or concave chamber, and/or specialised imaging
776 objectives with long working distances must be used. Alternative refractive index
777 matching solutions may also be considered.

778 **Acknowledgments**

779 We are grateful to members of the Fre laboratory, particularly Dr Silvia Fre (Institut Curie), for
780 support and constructive discussions. Protocols for optical tissue clearing and 3D imaging in
781 the mammary gland were developed in collaboration with Dr Felicity Davis (Mater Research

782 Institute, University of Queensland) and Professor Christine Watson (University of
783 Cambridge). We thank Marie Irondele and Lucie Sengmanivong (Institut Curie) for intravital
784 imaging support. We are also grateful to the Institut Curie In Vivo Experimental Facility for help
785 in the maintenance and care of mouse colonies. We acknowledge the Cell and Tissue Imaging
786 Platform (PICT-IBiSA) of the Genetics and Developmental Biology Department
787 (UMR3215/U934) and the Nikon Imaging Centre of Institut Curie, member of the French
788 National Research Infrastructure France-BioImaging (ANR10-INBS-04). B.L-L is supported by
789 the Academy of Medical Sciences, Wellcome Trust and the University of Bristol (Vice-
790 Chancellor's Research Fellowship). C.C is supported by funding from the European Union's
791 Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant
792 agreement No 666003.

793 **Ethics Statement**

794 All animal experimentation were carried out in accordance with the Animal (Scientific
795 Procedures) Act 1986/609 and with local ethics committee approval.

796

797 **References**

798

- 799 1. Neville MC (2009) Classic studies of mammary development and milk secretion:
800 1945-1980. *J. Mammary Gland Biol. Neoplasia* 14:193–197
- 801 2. Lloyd-Lewis B (2020) Multidimensional Imaging of Mammary Gland Development: A
802 Window Into Breast Form and Function. *Front. Cell Dev. Biol.* 8
- 803 3. Follain G, Mercier L, Osmani NL, et al (2017) Seeing is believing-multi-scale spatio-
804 temporal imaging towards in vivo cell biology. <https://doi.org/10.1242/jcs.189001>
- 805 4. Conchello JA, Lichtman JW (2005) Optical sectioning microscopy. *Nat. Methods*
806 2:920–931
- 807 5. Helmchen F, Denk W (2005) Deep tissue two-photon microscopy. *Nat. Methods*
808 2:932–940
- 809 6. Dunn KW, Young PA (2006) Principles of Multiphoton Microscopy. *Nephron Exp*
810 *Nephrol* 103:e33–e40. <https://doi.org/10.1159/000090614>
- 811 7. Lloyd-Lewis B, Harris OB, Watson CJ, Davis FM (2017) Mammary Stem Cells:
812 Premise, Properties, and Perspectives. *Trends Cell Biol.*
- 813 8. Fumagalli A, Bruens L, Scheele CLGJ, van Rheenen J (2019) Capturing Stem Cell
814 Behavior Using Intravital and Live Cell Microscopy. *Cold Spring Harb Perspect Biol*
815 a035949. <https://doi.org/10.1101/cshperspect.a035949>
- 816 9. Zomer A, Ellenbroek SIJ, Ritsma L, et al (2013) Brief Report: Intravital Imaging of
817 Cancer Stem Cell Plasticity in Mammary Tumors. *Stem Cells* 31:602–606.
818 <https://doi.org/10.1002/stem.1296>
- 819 10. Ellenbroek SIJ, Van Rheenen J (2014) Imaging hallmarks of cancer in living mice.
820 *Nat. Rev. Cancer* 14:406–418
- 821 11. Lloyd-Lewis B, Davis FM, Harris OB, et al (2016) Imaging the mammary gland and
822 mammary tumours in 3D: optical tissue clearing and immunofluorescence methods.
823 *Breast Cancer Res* 18:127. <https://doi.org/10.1186/s13058-016-0754-9>
- 824 12. Suijkerbuijk SJE, van Rheenen J (2017) From good to bad: Intravital imaging of the
825 hijack of physiological processes by cancer cells. *Dev. Biol.* 428:328–337
- 826 13. Pittet MJ, Weissleder R (2011) Intravital imaging. *Cell* 147:983–91.
827 <https://doi.org/10.1016/j.cell.2011.11.004>

- 828 14. Ewald AJ, Werb Z, Egeblad M (2011) Preparation of mice for long-term intravital
829 imaging of the mammary gland. *Cold Spring Harb Protoc* 6:
830 <https://doi.org/10.1101/pdb.prot5562>
- 831 15. Ewald AJ, Werb Z, Egeblad M (2011) Dynamic, long-term in vivo imaging of tumor-
832 stroma interactions in mouse models of breast cancer using spinning-disk confocal
833 microscopy. *Cold Spring Harb Protoc* 6: <https://doi.org/10.1101/pdb.top97>
- 834 16. Kedrin D, Gligorijevic B, Wyckoff J, et al (2008) Intravital imaging of metastatic
835 behavior through a mammary imaging window. *Nat Methods* 5:1019–1021.
836 <https://doi.org/10.1038/nmeth.1269>
- 837 17. Alieva M, Ritsma L, Giedt RJ, et al (2014) Imaging windows for long-term intravital
838 imaging: General overview and technical insights. *Intravital* 3:e29917.
839 <https://doi.org/10.4161/intv.29917>
- 840 18. Gligorijevic B, Kedrin D, Segall JE, et al (2009) Dendra2 photoswitching through the
841 mammary imaging window. *J Vis Exp*. <https://doi.org/10.3791/1278>
- 842 19. Ritsma L, A Steller EJ, J Ellenbroek SI, et al (2013) Surgical implantation of an
843 abdominal imaging window for intravital microscopy. *Nat Protoc*.
844 <https://doi.org/10.1038/nprot.2013.026>
- 845 20. Ritsma L, Steller EJA, Beerling E, et al (2012) Intravital microscopy through an
846 abdominal imaging window reveals a pre-micrometastasis stage during liver
847 metastasis. *Sci Transl Med* 4: <https://doi.org/10.1126/scitranslmed.3004394>
- 848 21. Kratochwil K (1969) Organ specificity in mesenchymal induction demonstrated in the
849 embryonic development of the mammary gland of the mouse. *Dev Biol* 20:46–71.
850 [https://doi.org/10.1016/0012-1606\(69\)90004-9](https://doi.org/10.1016/0012-1606(69)90004-9)
- 851 22. Hens JR, Dann P, Zhang JP, et al (2007) BMP4 and PTHrP interact to stimulate
852 ductal outgrowth during embryonic mammary development and to inhibit hair follicle
853 induction. *Development* 134:1221–1230. <https://doi.org/10.1242/dev.000182>
- 854 23. Voutilainen M, Lindfors PH, Mikkola ML (2013) Protocol: ex vivo culture of mouse
855 embryonic mammary buds. *J Mammary Gland Biol Neoplasia* 18:239–45.
856 <https://doi.org/10.1007/s10911-013-9288-2>
- 857 24. Scheele CLGJ, Hannezo E, Muraro MJ, et al (2017) Identity and dynamics of
858 mammary stem cells during branching morphogenesis. *Nature* 542:313–317.
859 <https://doi.org/10.1038/nature21046>

- 860 25. Wuidart A, Ousset M, Rulands S, et al (2016) Quantitative lineage tracing strategies
861 to resolve multipotency in tissue-specific stem cells. *Genes Dev* 30:1261–77.
862 <https://doi.org/10.1101/gad.280057.116>
- 863 26. Lilja AM, Rodilla V, Huyghe M, et al (2018) Clonal analysis of Notch1-expressing cells
864 reveals the existence of unipotent stem cells that retain long-term plasticity in the
865 embryonic mammary gland. *Nat Cell Biol* 20:677–687. [https://doi.org/10.1038/s41556-](https://doi.org/10.1038/s41556-018-0108-1)
866 [018-0108-1](https://doi.org/10.1038/s41556-018-0108-1)
- 867 27. Wuidart A, Sifrim A, Fioramonti M, et al (2018) Early lineage segregation of
868 multipotent embryonic mammary gland progenitors. *Nat Cell Biol* 20:666–676.
869 <https://doi.org/10.1038/s41556-018-0095-2>
- 870 28. Ke M-T, Fujimoto S, Imai T (2013) SeeDB: a simple and morphology-preserving
871 optical clearing agent for neuronal circuit reconstruction. *Nat Neurosci* 16:1154–61.
872 <https://doi.org/10.1038/nn.3447>
- 873 29. Susaki EA, Tainaka K, Perrin D, et al (2014) Whole-brain imaging with single-cell
874 resolution using chemical cocktails and computational analysis. *Cell* 157:726–39.
875 <https://doi.org/10.1016/j.cell.2014.03.042>
- 876 30. Davis FM, Lloyd-Lewis B, Harris OB, et al (2016) Single-cell lineage tracing in the
877 mammary gland reveals stochastic clonal dispersion of stem/progenitor cell progeny.
878 *Nat Commun* 7:13053. <https://doi.org/10.1038/ncomms13053>
- 879 31. Lloyd-Lewis B, Davis FM, Harris OB, et al (2018) Neutral lineage tracing of
880 proliferative embryonic and adult mammary stem/progenitor cells. *Development*
881 145:dev164079. <https://doi.org/10.1242/dev.164079>
- 882 32. Elias S, Morgan MA, Bikoff EK, Robertson EJ (2017) Long-lived unipotent Blimp1-
883 positive luminal stem cells drive mammary gland organogenesis throughout adult life.
884 *Nat Commun* 8:1714. <https://doi.org/10.1038/s41467-017-01971-w>
- 885 33. Hitchcock JR, Hughes K, Harris OB, Watson CJ (2019) Dynamic architectural
886 interplay between leucocytes and mammary epithelial cells. *FEBS J* febs.15126.
887 <https://doi.org/10.1111/febs.15126>
- 888 34. Stewart TA, Hughes K, Hume DA, Davis FM (2019) Developmental Stage-Specific
889 Distribution of Macrophages in Mouse Mammary Gland. *Front Cell Dev Biol* 7:.
890 <https://doi.org/10.3389/fcell.2019.00250>
- 891 35. Stevenson AJ, Vanwalleghem G, Stewart TA, et al (2019) Multiscale activity imaging

- 892 in the mammary gland reveals how oxytocin enables lactation. bioRxiv 657510.
893 <https://doi.org/10.1101/657510>
- 894 36. Barker N, Van Es JH, Kuipers J, et al (2007) Identification of stem cells in small
895 intestine and colon by marker gene Lgr5. *Nature* 449:1003–1007.
896 <https://doi.org/10.1038/nature06196>
- 897 37. Muzumdar MD, Tasic B, Miyamichi K, et al (2007) A global double-fluorescent Cre
898 reporter mouse. *genesis* 45:593–605. <https://doi.org/10.1002/dvg.20335>
- 899 38. Masedunskas A, Milberg O, Porat-Shliom N, et al (2012) Intravital microscopy: A
900 practical guide on imaging intracellular structures in live animals. *Bioarchitecture*
901 2:143–157. <https://doi.org/10.4161/bioa.21758>
- 902 39. Ewald AJ, Werb Z, Egeblad M (2011) Monitoring of vital signs for long-term survival of
903 mice under anesthesia. *Cold Spring Harb Protoc* 6:
904 <https://doi.org/10.1101/pdb.prot5563>
- 905 40. Snippert HJ, van der Flier LG, Sato T, et al (2010) Intestinal crypt homeostasis results
906 from neutral competition between symmetrically dividing Lgr5 stem cells. *Cell*
907 143:134–44. <https://doi.org/10.1016/j.cell.2010.09.016>
- 908 41. Ritsma L, Vrisekoop N, van Rheenen J (2013) In vivo imaging and histochemistry are
909 combined in the cryosection labelling and intravital microscopy technique. *Nat*
910 *Commun* 4:2366. <https://doi.org/10.1038/ncomms3366>
- 911 42. Watson CJ, Khaled WT (2008) Mammary development in the embryo and adult: a
912 journey of morphogenesis and commitment. *Development* 135:995–1003.
913 <https://doi.org/10.1242/dev.005439>
- 914 43. Panchal H, Wansbury O, Howard BA (2010) Embryonic mammary anlagen analysis
915 using immunolabelling of whole mounts. *Methods Mol Biol* 585:261–270.
916 https://doi.org/10.1007/978-1-60761-380-0_18
- 917 44. Matryba P, Kaczmarek L, Gołab J (2019) Advances in Ex Situ Tissue Optical
918 Clearing. *Laser Photon Rev* 1800292. <https://doi.org/10.1002/lpor.201800292>
- 919 45. Perrin L, Bayarmagnai B, Gligorijevic B (2019) Frontiers in intravital multiphoton
920 microscopy of cancer. *Cancer Rep*. <https://doi.org/10.1002/cnr2.1192>
- 921 46. Tainaka K, Murakami TC, Susaki EA, et al (2018) Chemical Landscape for Tissue
922 Clearing Based on Hydrophilic Reagents. *Cell Rep* 24:2196-2210.e9.
923 <https://doi.org/10.1016/j.celrep.2018.07.056>

- 924 47. Ke MT, Nakai Y, Fujimoto S, et al (2016) Super-Resolution Mapping of Neuronal
925 Circuitry With an Index-Optimized Clearing Agent. *Cell Rep* 14:2718–2732.
926 <https://doi.org/10.1016/j.celrep.2016.02.057>
- 927 48. Rios AC, Capaldo BD, Vaillant F, et al (2019) Intracloal Plasticity in Mammary
928 Tumors Revealed through Large-Scale Single-Cell Resolution 3D Imaging. *Cancer*
929 *Cell* 35:618-632.e6. <https://doi.org/10.1016/J.CCELL.2019.02.010>

930

931 **Figure Legends**

932

933 **Figure 1. Intravital imaging through the mammary imaging window (MIW).** (a) Schematic
934 representation of the surgical procedure. 1. Make an incision above the 4th mammary gland.
935 2. Place a purse-string suture around the incision. Dotted line denotes internal suture position.
936 3. Insert the MIW above the mammary gland and place the sutured skin within the groove.
937 Secure the skin around the MIW by tightening the purse-string suture. Protocol based on [17,
938 19]. (b) Photograph of the MIW implanted over the 4th abdominal mammary gland. LN; Lymph
939 Node. (c) Longitudinal imaging of mammary epithelial cell dynamics by multiphoton IVM.
940 Images show a mammary epithelial duct in a 5 week old *K5-Cre^{ERT2};Rosa26-mTmG* female
941 mouse. In this model, all cells are labelled with a membrane-bound Tomato fluorescent protein
942 (mT, red). Tamoxifen administration induces Cre-mediated recombination of the reporter allele
943 in sporadic Keratin (K)5-expressing mammary myoepithelial cells, resulting in membrane-
944 bound EGFP fluorescent protein expression (mG, green). Images show the migratory
945 behaviour of four EGFP⁺ mammary myoepithelial cells over time. Second harmonic
946 generation (SHG) microscopy reveal the collagen organisation surrounding the ductal
947 structure. Scale bars: 100 μ m (left panels), 25 μ m (right panels).

948 **Figure 2. Embryonic mammary gland dissection protocol.** (1) Collect all embryos from
949 the uterus of a pregnant female mouse. (2) Attach the decapitated embryo to a dish filled with
950 set silicon. (3) Remove the limbs. (4) Cut along the dorsal-lateral line of the embryo (dashed
951 line). (5) Detach the flank (see arrowheads) to the midline. (6) Collect both flanks of the embryo
952 containing the embryonic mammary buds (marked with dashed circles). (7) Remove skin
953 epithelium after enzymatic digestion with pancreatic-trypsin working solution. Dashed circles
954 denote the location of embryonic mammary buds within the mesenchyme. (8) Culture the
955 isolated tissues on an air-liquid interface. Protocol based on [23].

956 **Figure 3. 4D ex vivo imaging of mammary embryonic bud cultures** (a) Longitudinal
957 fluorescence imaging of embryonic mammary branching morphogenesis. Schematic
958 representation of the microscope configuration for live-cell imaging of embryonic mammary

959 bud cultures. The tissue (i) is deposited on a cell culture insert (ii) placed in contact with the
960 culture medium (iii) in a glass bottom dish. Use an inverted confocal or multiphoton microscope
961 equipped with a long-working distance objective for imaging. Images show the growth of an
962 E15.5 embryonic mammary bud isolated from a *Lgr5-GFP* [36] mouse embryo over 5 days.
963 Maximum intensity projections of image sequences are displayed, and the rendered surface
964 of the mammary epithelium is outlined in white. Scale bars: 100 μm . **(b)** Time-lapse imaging
965 of embryonic mammary cultures. Close-up of one embryonic mammary bud dissected from a
966 *Rosa26-mTmG* [37] mouse embryo at day E13.5, and cultured *ex vivo* for 5 days prior to time-
967 lapse imaging. Images show the growth of an epithelial branch over 10 h (white box). In this
968 reporter mouse strain, all cells are labelled with a membrane-bound Tomato fluorescent
969 protein (red). Inset images show a thin optical slice. Individual mammary epithelial cells can
970 be clearly visualised in *ex vivo* cultures by high-resolution multiphoton microscopy. Branching
971 morphogenesis can be monitored for up to 24 h by time-lapse confocal or multiphoton imaging.
972 The rendered surface of the mammary epithelium is outlined in white. Scale bars: 100 μm .

973 **Figure 4: Wholemout immunostaining of embryonic mammary cultures.**
974 Immunofluorescence staining of an embryonic mammary gland dissected at day E13.5 and
975 grown in *ex vivo* culture for 8 days. Left panel: Maximum intensity projection (MIP) showing
976 the expression of the luminal epithelial marker protein Keratin 8 (K8, red), and the basal
977 epithelial marker protein p63 (green) in embryonic mammary cells. Nuclei are stained with
978 DAPI (blue). Centre panel: A single optical section (z). White boxes mark regions displayed in
979 the right panels. Scale bar: 100 μm . Right panel: Close-up images of K8 (red) and p63 (green)
980 expressing cells in a tip (upper panel) and branch (lower panel) region of the embryonic
981 mammary epithelium. Scale bar: 25 μm .

982 **Figure 5: Clear unobstructed brain imaging cocktails (CUBIC) optical clearing and 3D**
983 **imaging of mouse mammary tissues. (a)** CUBIC optical tissue clearing and immunostaining
984 protocol and timeline. Black arrow shows the stage at which (optional) immunostaining may
985 be performed. The experimental timeline may be adapted depending on the desired degree
986 of transparency, and the size and nature of the tissue. **(b)** Transmission images of whole
987 abdominal (4th) virgin and lactating mammary glands, before and after CUBIC clearing.
988 Adapted from [11] with permission from Springer under
989 <http://creativecommons.org/licenses/by/4.0/>. **(c)** Example three-dimensional confocal images
990 of cleared mammary tissues immunostained with basal mammary epithelial cell markers (K5
991 or smooth muscle actin (SMA)) showing compatibility of CUBIC clearing with high-resolution
992 imaging of genetically-encoded fluorescent proteins. Top panels show a close up image of a
993 mammary duct in a virgin *SMA-Cre^{ERT2}; Rosa26-mTmG* reporter mouse. Membrane labelling
994 in recombined (mG, green) mammary basal cells can be observed at high resolutions by

995 CUBIC clearing. Non-recombined cells express membrane-bound Tomato fluorescent protein
996 (mT, red). Middle and bottom panels show 3D images of cleared mammary tissues from
997 involuting and lactating *R26R-Confetti* fluorescent reporter mice respectively. Reporter
998 expression (nuclear GFP, cytosolic YFP and cytosolic RFP) is induced at low, sporadic levels.
999 Scale bars: 50 μm (top two panels), 100 μm (middle and bottom panels). MIP, maximum
1000 intensity projection; z, single optical section.

1001 **Figure 6:** See deep brain (*SeeDB*)-clearing and 3D imaging of mouse mammary tissues
1002 **(a)** *SeeDB* tissue clearing and immunostaining protocol and timeline. Black arrow shows the
1003 stage at which (optional) immunostaining may be performed. The experimental timeline may
1004 be adapted depending on the desired degree of transparency, and the size and nature of the
1005 tissue. **(b)** Transmission images of whole abdominal (4th) virgin and lactating mammary
1006 glands, before and after *SeeDB* clearing. Adapted from [11] with permission from Springer
1007 under <http://creativecommons.org/licenses/by/4.0>. **(c)** Example three-dimensional confocal
1008 images of *SeeDB*-cleared mammary tissues immunostained with a basal cell marker (SMA)
1009 showing compatibility of *SeeDB* clearing with high-resolution imaging of genetically-encoded
1010 fluorescent proteins. Top and middle panels show images of the mammary epithelium in virgin
1011 and pregnant *N1-Cre^{ERT2}; Rosa26-mTmG* reporter mice respectively. Membrane labelling in
1012 recombined (mG, green) and unrecombined (mT, red) mammary luminal cells can be
1013 observed at high resolutions. Bottom panels show images of *SeeDB*-cleared mammary
1014 tissues from a lactating *Rosa26-YFP* mouse model immunostained with a GFP antibody. MIP,
1015 maximum intensity projection; z, single optical section. Scale bars: 50 μm .

1016

1017

1018

1019

1020

1021

1022

1023